Which has stronger earnings & valuation, LBRX or MANE?

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A Veradermics N/A N/A -$70M -$1.32 N/A

Is LBRX or MANE more profitable?

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.96% -25.03% Veradermics N/A N/A N/A

Does the media prefer LBRX or MANE?

In the previous week, LB Pharmaceuticals had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat LB Pharmaceuticals' score of 0.43 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, LBRX or EWTX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is LBRX or EWTX more profitable?

LB Pharmaceuticals' return on equity of -25.96% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.96% -25.03% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media prefer LBRX or EWTX?

In the previous week, Edgewise Therapeutics had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 14 mentions for Edgewise Therapeutics and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Edgewise Therapeutics' score of 0.13 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LBRX or DFTX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is LBRX or DFTX more profitable?

LB Pharmaceuticals' return on equity of -25.96% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.96% -25.03% Definium Therapeutics N/A -84.01% -63.66%

Does the media prefer LBRX or DFTX?

In the previous week, Definium Therapeutics had 41 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 51 mentions for Definium Therapeutics and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Definium Therapeutics' score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 10 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer LBRX or INDV?

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Indivior. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 6 mentions for Indivior. Indivior's average media sentiment score of 1.32 beat LB Pharmaceuticals' score of 0.43 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LB Pharmaceuticals (LBRX) Competitors

$47.34 +3.07 (+6.93%)

As of 03:25 PM Eastern

Compare

LBRX vs. MANE, EWTX, DFTX, INDV, and CPRX

Should you buy LB Pharmaceuticals stock or one of its competitors? LB Pharmaceuticals's main competitors and comparable companies include Veradermics (MANE), Edgewise Therapeutics (EWTX), Definium Therapeutics (DFTX), Indivior (INDV), and Catalyst Pharmaceuticals (CPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LB Pharmaceuticals compare to Veradermics?

LB Pharmaceuticals (NASDAQ:LBRX) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, LB Pharmaceuticals had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat LB Pharmaceuticals' score of 0.43 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.96%	-25.03%
Veradermics	N/A	N/A	N/A

LB Pharmaceuticals presently has a consensus price target of $47.75, indicating a potential upside of 1.46%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 35.93%. Given Veradermics' higher probable upside, analysts clearly believe Veradermics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

Summary

LB Pharmaceuticals and Veradermics tied by winning 5 of the 10 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Edgewise Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Edgewise Therapeutics had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 14 mentions for Edgewise Therapeutics and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Edgewise Therapeutics' score of 0.13 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

LB Pharmaceuticals' return on equity of -25.96% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.96%	-25.03%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

LB Pharmaceuticals currently has a consensus target price of $47.75, indicating a potential upside of 1.46%. Edgewise Therapeutics has a consensus target price of $49.08, indicating a potential upside of 12.22%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

LB Pharmaceuticals beats Edgewise Therapeutics on 6 of the 10 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Definium Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

LB Pharmaceuticals presently has a consensus target price of $47.75, suggesting a potential upside of 1.46%. Definium Therapeutics has a consensus target price of $62.14, suggesting a potential upside of 47.75%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 41 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 51 mentions for Definium Therapeutics and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Definium Therapeutics' score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	10 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

27.9% of Definium Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

LB Pharmaceuticals' return on equity of -25.96% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.96%	-25.03%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Definium Therapeutics beats LB Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Indivior?

LB Pharmaceuticals (NASDAQ:LBRX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Indivior has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Indivior	$1.24B	3.69	$210M	$2.79	13.88

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Indivior. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 6 mentions for Indivior. Indivior's average media sentiment score of 1.32 beat LB Pharmaceuticals' score of 0.43 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a net margin of 26.65% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.96% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.96%	-25.03%
Indivior	26.65%	-283.11%	36.85%

60.3% of Indivior shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LB Pharmaceuticals presently has a consensus target price of $47.75, suggesting a potential upside of 1.46%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 16.60%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Indivior beats LB Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Catalyst Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Catalyst Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LB Pharmaceuticals currently has a consensus target price of $47.75, suggesting a potential upside of 1.46%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Catalyst Pharmaceuticals' higher probable upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, LB Pharmaceuticals had 10 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 10 mentions for LB Pharmaceuticals and 0 mentions for Catalyst Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Catalyst Pharmaceuticals' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
LB Pharmaceuticals	Neutral
Catalyst Pharmaceuticals	Neutral

Catalyst Pharmaceuticals has a net margin of 37.08% compared to LB Pharmaceuticals' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.96%	-25.03%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summary

Catalyst Pharmaceuticals beats LB Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.51B	$11.74B	$6.99B	$13.03B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-13.65	781.46	269.55	25.26
Price / Sales	N/A	748.20	597.75	101.23
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	3.95	10.76	13.08	6.33
Net Income	-$25.20M	$2.77B	$3.45B	$347.70M
7 Day Performance	-1.95%	0.05%	1.02%	0.97%
1 Month Performance	46.99%	0.20%	1.68%	0.92%
1 Year Performance	N/A	161.31%	67.42%	20.45%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	1.0475 of 5 stars	$47.34 +6.9%	$47.75 +0.9%	N/A	$1.53B	N/A	N/A	16	Earnings Report Analyst Downgrade
MANE Veradermics	2.3771 of 5 stars	$110.72 -3.2%	$153.00 +38.2%	N/A	$4.78B	N/A	N/A	19	Earnings Report Gap Down
EWTX Edgewise Therapeutics	2.1051 of 5 stars	$44.58 +2.4%	$48.75 +9.4%	+214.5%	$4.73B	N/A	N/A	60	Positive News Analyst Forecast
DFTX Definium Therapeutics	3.0462 of 5 stars	$45.15 -2.1%	$55.00 +21.8%	+340.3%	$4.60B	N/A	N/A	40	Trending News Analyst Forecast Analyst Revision
INDV Indivior	4.0886 of 5 stars	$38.47 -0.9%	$45.17 +17.4%	+66.4%	$4.58B	$1.24B	13.79	1,051	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. MANE, EWTX, DFTX, INDV, and CPRX

How does LB Pharmaceuticals compare to Veradermics?

Summary

How does LB Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Summary

How does LB Pharmaceuticals compare to Indivior?

Summary

How does LB Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. MANE, EWTX, DFTX, INDV, and CPRX

How does LB Pharmaceuticals compare to Veradermics?

Does the media prefer LBRX or MANE?

Is LBRX or MANE more profitable?

Do analysts prefer LBRX or MANE?

Which has stronger earnings & valuation, LBRX or MANE?

Summary

How does LB Pharmaceuticals compare to Edgewise Therapeutics?

Does the media prefer LBRX or EWTX?

Which has better valuation & earnings, LBRX or EWTX?

Is LBRX or EWTX more profitable?

Do analysts prefer LBRX or EWTX?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Do analysts rate LBRX or DFTX?

Does the media prefer LBRX or DFTX?

Do insiders and institutionals hold more shares of LBRX or DFTX?

Which has better earnings & valuation, LBRX or DFTX?

Is LBRX or DFTX more profitable?

Summary

How does LB Pharmaceuticals compare to Indivior?

Which has preferable earnings & valuation, LBRX or INDV?

Does the media prefer LBRX or INDV?

Is LBRX or INDV more profitable?

Do institutionals & insiders hold more shares of LBRX or INDV?

Do analysts recommend LBRX or INDV?

Summary

How does LB Pharmaceuticals compare to Catalyst Pharmaceuticals?

Which has stronger valuation & earnings, LBRX or CPRX?

Do institutionals and insiders hold more shares of LBRX or CPRX?

Do analysts recommend LBRX or CPRX?

Does the media prefer LBRX or CPRX?

Is LBRX or CPRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools